Home・Listă Acțiuni・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Închisă

SectorSănătate

59.29 0.88

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

58.66

Maxim

59.32

Indicatori cheie
By Trading Economics
Venit	-34M 106M
Vânzări	-108M 766M
P/E Medie Sector	42.833 62.58
EPS	0.76
Marjă de profit	13.773
Angajați	3,221
EBITDA	177M 173M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+47.07% upside

Dividende
By Acuity
Următoarele câștiguri	3 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	1B 11B
Deschiderea anterioară	58.41
Închiderea anterioară	59.29

Sentimentul știrilor

By Acuity

50%

163 / 340 Clasament în Healthcare

BioMarin Pharmaceutical Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 iul. 2026, 15:46 UTC

Biomarin Pharmaceutical shares are higher today, reflecting a broader market rebound amid a significant decline in oil prices.

22 iul. 2026, 23:31 UTC

Biomarin Pharmaceutical shares traded roughly flat in after-market hours amid rising crude oil prices and geopolitical tensions affecting market sentiment.

21 iul. 2026, 15:36 UTC

Biomarin Pharmaceutical Inc shares are higher as the Nasdaq gains, supported by strong technology stocks. The stock trades above its 20-day moving average.

20 iul. 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, remaining above their 20-day moving average amid broader market concerns over interest rates and economic growth.

16 iul. 2026, 19:06 UTC

Macro Event

News

Citi analyst raises price target on Biomarin Pharmaceutical to $76.00, maintaining a Buy rating. Shares are higher today amid positive sentiment and notable volatility.

15 iul. 2026, 23:21 UTC

Biomarin Pharmaceutical shares are higher in after-market trading, nearing the upper end of their one-month range amid broader market concerns over geopolitical tensions.

14 iul. 2026, 19:31 UTC

Event

Biomarin Pharmaceutical shares are lower today, tracking declines in the Biotechnology sub-sector, continuing a downward trend since Monday's close.

13 iul. 2026, 19:46 UTC

News

Event

BioMarin Pharmaceutical's supplemental New Drug Application for VOXZOGO has been accepted by the FDA. Shares are lower today amid broader market sentiment.

10 iul. 2026, 23:46 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, retracing from earlier highs. No specific news was identified to explain the movement.

9 iul. 2026, 19:16 UTC

Biomarin Pharmaceutical Inc. shares are trading roughly flat with no specific news identified. The stock remains above its 20-day moving average.

8 iul. 2026, 23:46 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting routine trading activity with minimal fluctuations and positioning above the 20-day moving average.

7 iul. 2026, 23:32 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market trading, reflecting routine activity despite broader market volatility following Samsung Electronics' disappointing news.

6 iul. 2026, 20:06 UTC

Biomarin Pharmaceutical shares are lower today, continuing a decline since Thursday. No specific news was identified to explain the trading activity.

2 iul. 2026, 22:51 UTC

Biomarin Pharmaceutical Inc. shares were roughly flat in after-market trading, with no specific news identified. The stock has shown little change since Thursday's close.

1 iul. 2026, 19:36 UTC

Biomarin Pharmaceutical Inc's shares are higher today, reaching a notable intraday high amid broader market caution and no specific company news identified.

30 iun. 2026, 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

29 iun. 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, retracing from earlier gains amid mixed U.S. equity performance and broader inflation concerns.

26 iun. 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 iun. 2026, 23:31 UTC

Biomarin Pharmaceutical shares declined in after-market trading, despite remaining above the 20-day moving average and near the upper end of its one-month range.

24 iun. 2026, 19:41 UTC

Biomarin Pharmaceutical Inc is gaining Wednesday, supported by strong momentum in the Biotechnology sub-sector, despite an earlier decline in the session.

23 iun. 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. Broader market sentiment is affected by declines in Asian markets amid tech sector concerns.

22 iun. 2026, 23:56 UTC

Biomarin Pharmaceutical shares showed little change in after-market trading. The stock remains within the middle of its one-month trading range.

19 iun. 2026, 00:01 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market hours, recovering from earlier lows and reflecting strong performance since Thursday's close.

18 iun. 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close despite earlier fluctuations in the session.

17 iun. 2026, 20:08 UTC

Event

Biomarin Pharmaceutical is trading lower amid broader market declines, despite presenting new data on VOXZOGO® and BMN 333 at the ENDO 2026 conference.

16 iun. 2026, 23:41 UTC

Event

Biomarin Pharmaceutical presented new data on investigational therapies at the Endocrine Society Annual Meeting. Shares showed little change during after-market hours.

15 iun. 2026, 13:26 UTC

Biomarin Pharmaceutical Inc is trading higher in pre-market hours, reflecting positive momentum amid a broader upward trend in Asian markets, including a surge in the Nikkei Index.

13 iun. 2026, 00:01 UTC

Biomarin Pharmaceutical Inc shares declined in after-market trading, retracing from earlier gains while remaining above the 20-day moving average. No specific news was identified.

12 iun. 2026, 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

11 iun. 2026, 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, reaching an early session low. Broader economic news includes an unexpected rise in initial jobless claims.

Comparație

Modificare preț

BioMarin Pharmaceutical Inc Așteptări

Obiectiv de preț

By TipRanks

47.07% sus

Prognoză pe 12 luni

Medie 86.58 USD 47.07%

Maxim 120 USD

Minim 50 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBioMarin Pharmaceutical Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 20 analiști care au acordat evaluări ale acțiunilor BioMarin Pharmaceutical Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

163 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.